When a Sample Lot Is Not the Commercial Lot: Why an ISO 11135:2014 Cycle File and FDA Rec 14-529 Do Not Adopt a New Size, Blister or Load, Why AAMI TIR28 Rec 14-603 Is the Product-Adoption Overlay, Why Annex E Single-Batch Release Is Not Adoption, and Why ISO/FDIS 11135 Is Not the Cycle File

In international medical device distribution and contract manufacturing, one scenario recurs with striking predictability. An overseas distributor, hospital tender committee, or OEM private-label brand evaluates a 50-piece sample consignment of an ethylene oxide (EO) sterilized single-use device—such as an outpatient circumcision ring, anastomat kit, or surgical trocar. Accompanying the evaluation shipment is a pristine Certificate of Conformity and an ISO 11135:2014 cycle validation report issued by a renowned contract sterilization provider.² The evaluation succeeds, surgical feedback is favorable, and the buyer issues a commercial purchase order for a full production lot of 5,000 units.¹¹

However, the commercial purchase order introduces a critical operational delta: it specifies a Children size run (for example a 12 mm ring rather than the Adult 26 mm model evaluated in the clinic), a modified blister, or a denser pallet configuration than the sample shipment.¹¹ When the buyer's quality engineering team requests the updated sterilization file prior to customs clearance, the vendor replies with reassuring brevity: 'The sterilization cycle is already certified under ISO 11135:2014; all sizes belong to the same product family and are covered under our existing FDA and CE cycle files.'

That single assertion is one of the most consequential incoming-inspection errors on sterile consignments. An ISO 11135:2014 cycle file proves only that an industrial sterilization cycle exists and was qualified for a specific master product or internal process challenge device (PCD).² It does not, by itself, demonstrate that a new size variant, a modified blister, or a denser pallet load can be processed under that cycle.¹¹⁰ Navigating that gap requires the Rec 14-529 cycle file, the Rec 14-603 TIR28 overlay, a refusal to treat Annex E single-batch release as adoption, and the knowledge that ISO/FDIS 11135 is unpublished.¹⁴

Does an ISO 11135:2014 cycle certificate, or FDA Rec 14-529, adopt a new size, blister or load into the validated EO family?

The short answer is no. ISO 11135:2014—formally recognized by the United States Food and Drug Administration (FDA) under Recognition Number 14-529—is the international consensus standard governing the development, validation, and routine control of ethylene oxide sterilization processes for medical devices.²⁸ A completed Rec 14-529 cycle file shows that a process was developed, validated and placed under routine control for a defined family, master product or internal process challenge device (PCD). Half-cycle overkill tables, biological-indicator placement and parametric-release rules belong to the ISO 11135 cycle-acceptance neighbour, not this adoption overlay: see ISO 11135 ethylene-oxide cycle validation acceptance. A Union-bound cycle citation remains EN ISO 11135:2014/A1:2019 as already used in our residual-edition neighbour; TIR28 is not that Official Journal cell.

Once established, that cycle validation file proves that a validated physical cycle exists for a defined device family, master product and internal PCD under the loading pattern and packaging configuration evaluated in the original runs.² It does not, by itself, adopt a newly quoted size, blister or load. Quoting a cycle certificate for an unvalidated SKU confuses the Rec 14-529 cycle file with the Rec 14-603 adoption overlay.¹

The Engineering Gap: Why Cycle Files Do Not Self-Adopt New Products

When a factory manufactures a new catalog number or alters a physical dimension, three physical variables immediately diverge from the validated cycle baseline:¹⁰

• Internal Challenge to Gas Penetration: If a Children size has tighter internal clearances or smaller lumens than the Adult device originally validated as the master product, gas and moisture kinetics can change.
• Packaging Barrier and Cavity Headspace: If an evaluation sample was packed in a loose pouch while the commercial production lot is sealed inside a rigid PETG/Tyvek blister tray with high-density foam inserts, the breathability area and gas diffusion path are radically altered.
• Total Chamber Gas Depletion: A denser commercial polymer load can absorb more ethylene oxide during dwell than a sparsely loaded sample run, changing chamber concentration unless the load was the mapped challenge.

FDA Rec 14-529 completely recognizes ISO 11135:2014 including Amendment 1:2018 as the cycle-development, validation and routine-control file.² FDA Rec 14-603 separately and completely recognizes AAMI TIR28:2016/(R)2020 for product adoption and process equivalence for ethylene oxide sterilization, and the Rec 14-603 SIS names that TIR as relevant to the ISO 11135 series in those two areas.¹ Those are two Rec-number cells, not one certificate. Table 1 splits the incoming file.

What does FDA Rec 14-603 actually recognize, and why is AAMI TIR28:2016/(R)2020 not the same string as the shop-window (R)2024 reaffirmation?

To establish a rigorous, auditable bridge between an existing validated cycle and a new product SKU, international medical device manufacturers turn to Association for the Advancement of Medical Instrumentation (AAMI) Technical Information Report 28 (TIR28).¹¹⁰ On 29 May 2024, under Federal Register Recognition List 062, the US FDA entered Recognition Number 14-603 into its Recognized Consensus Standards database.¹

As verified in the FDA Supplementary Information Sheet (SIS, standard identification 45510) and confirmed in the 26 August 2026 recognized-standards snapshot (1,898 rows across all specialties), Rec 14-603 grants Complete recognition to AAMI TIR28:2016/(R)2020: Product adoption and process equivalence for ethylene oxide sterilization.¹⁹ It carries no transition expiration date in that snapshot.¹ Those two title tasks—adopting a candidate into an existing EO family, and process equivalence across equipment—are the Rec 14-603 overlay. The paywalled TIR body is not reconstructed here; STERIS's public TechTip remains the SERP HOW for family, worst-case or PCD, and greater-challenge full PQ.¹⁰

The Designation Split: Official Rec 14-603 Designation vs (R)2024 Shop Windows

In recent months, a discrepancy has emerged between commercial storefronts, search-engine summaries, and the FDA SIS.¹ AAMI's public catalogue currently lists the document as AAMI TIR28:2016/(R)2024. That shop-window string is a reaffirmation year; it is not proof that Rec 14-603 has moved.

However, regulatory recognition does not update automatically through commercial webstore listings.¹ FDA CDRH's official consensus recognition under Rec 14-603 specifically designates AAMI TIR28:2016/(R)2020.¹ For a US 510(k) declaration of conformity, the designation string should match the SIS cell. A shop-window (R)2024 citation is not Rec 14-603. This page does not invent a technical delta between the two reaffirmation years.

Even more dangerous is the presence of obsolete citations in commercial supplier files. A noticeable number of overseas factory quality manuals still cite AAMI TIR28:2009 (R2013), a version that continues to linger in organic search results on ANSI webstore pages. Citing a 2009 technical information report is not Rec 14-603. The full citation matrix is summarized in Table 2.

Why is ISO 11135:2014/Amd 1:2018 Annex E single-batch release a different instrument from TIR28 product adoption?

When quality inspectors and international buyers challenge an offshore manufacturer on why a new commercial size code has no product adoption file, a frequent vendor response points to Amendment 1 of ISO 11135: 'Our quality system releases newly added SKUs under ISO 11135 Amendment 1 Annex E, which is fully recognized by FDA under Rec 14-529.'²⁴

This is the wrong Rec-number cell. In 2018, ISO published Amendment 1 to ISO 11135:2014 (catalogue 70821, stage 60.60), titled Amendment 1: Revision of Annex E, Single batch release.⁴ FDA CDRH recognizes that identical AAMI adoption as ANSI/AAMI/ISO 11135:2014/A1:2018 under Rec 14-529.² Rec 14-603 is a different row: AAMI TIR28:2016/(R)2020, product adoption and process equivalence.¹

Why Annex E is not TIR28 product adoption

The public sources stop at that title. They do not publish Annex E's protocol tables, biological-indicator counts, or a list of permitted use cases, and this page does not reconstruct them.⁴ What an incoming inspector can still decide from the Rec numbers is narrower: a file titled Single batch release is not a Rec 14-603 adoption rationale for a new commercial size, blister or load.

The title itself is the operational gate: single batch. Offering Annex E as a standing method for adding catalog SKUs confuses Rec 14-529's amendment with Rec 14-603.²¹ STERIS's public TechTip, by contrast, treats product adoption as a comparison against a worst-case family representative or PCD, with full PQ if the candidate is a greater challenge.¹⁰ Using Annex E as a substitute for that overlay also fails ISO 13485 Clause 7.5.6 as a process-validation file. Under QMSR, 21 CFR 820.75 is reserved and is not the current US section number; see QMSR production and process-control file review before the first commercial lot.

The remaining Annex E boundary is the same as the title: release of one identified batch is not adoption of the next lot, and it is not Rec 14-603.² Demand the TIR28 adoption rationale or a documented greater-challenge PQ for the quoted commercial configuration; refuse Annex E as that overlay.

Is ISO/FDIS 11135, or the cancelled ISO/DIS 11135, the cycle file on 12 September 2026?

Another pervasive argument encountered during supplier audits involves the revision roadmap of ISO 11135. Factory regulatory managers sometimes state: 'Our sterilization documentation follows the new ISO 11135 third edition, which modernizes product adoption and incorporates flexible family grouping.'

That claim is false on the public catalogues.⁵ ISO/TC 198 balloted a draft third edition, cataloged as ISO/DIS 11135 (catalogue 81509). After two DIS ballots, ISO updated the status to Deleted, with project cancellation at stage 40.98 on 16 May 2024.⁵ The public record does not convert that cancellation into a published third-edition cycle file.

The Official ISO Catalogue Lineage: What Is Actually in Force in September 2026

Following the cancellation of the DIS draft, ISO opened a successor project: ISO/FDIS 11135 (catalogue 90088).⁶ According to ICS 11.080.01, ISO/FDIS 11135 sits under development at stage 50.00.⁷ It has not reached formal publication and is not Rec 14-529.⁶⁹

Therefore, on 12 September 2026, the published cycle edition remains ISO 11135:2014 (Second Edition) including Amendment 1:2018 (catalogue 56137, stage 90.92).³ Any supplier asserting compliance with 'ISO 11135 Edition 3' is referencing either a cancelled draft (81509) or an unpublished work-in-progress (90088).⁵⁶ Chart 1 records the bounded Rec-number census used to check those two cells against neighbouring sterility rows.

Why is a 50-piece sample not a validated load, worst-case product or process challenge device?

The most common operational divergence in B2B procurement occurs between the evaluation sample and the commercial order. A hospital, distributor, or OEM buyer receives a 50-piece evaluation lot of single-use circumcision devices or anastomat kits.¹¹¹³ Those units were processed under sterile conditions, but a 50-piece sample is not, without further evidence, the validated commercial load, worst-case product or internal PCD.

Processing 50 units in a loose box is a different load configuration from a palletized commercial order. STERIS's public TechTip lists design, materials, sterile barrier and load configuration among the differences to assess, and it requires full PQ if the candidate is a greater challenge.¹⁰ A first commercial lot that changes size, blister or pallet density is that assessment, not a closed sample certificate.

Six Physical and Microbiological Failure Modes in Commercial Scale-Up

When moving from sample quantities to palletized commercial consignments, quality engineers should treat the following as load-configuration questions, not as reconstructed TIR28 Annex tables:¹⁰

1. Thermal inertia: A small evaluation carton reaches preconditioning temperature faster than a dense commercial pallet of corrugated shippers. If the commercial load was not the mapped challenge, center-of-load temperature and humidity can lag the chamber sensors.
2. Moisture and relative humidity: Ethylene oxide lethality depends on moisture reaching the challenge location. Additional corrugated layers and lidding change the path relative to a loosely packed sample.
3. Sterilant diffusion: Gas must move through shipper, carton, blister or pouch, and device geometry. Pallet wraps and denser stacking are load-configuration changes of the kind STERIS lists for adoption review.
4. Polymer absorption and chamber dosing: Additional polymer mass can absorb sterilant during dwell. If the gas charge was qualified on a lighter sample load, the commercial pallet is a different challenge.
5. Internal PCD representation: Rec 14-529 cycle files are built around a defined master product or internal PCD. External spore strips on a 50-piece sample do not, by themselves, prove that the commercial SKU is that challenge device.
6. Aeration and residuals: Residual dissipation scales with polymer mass, packaging and pallet spacing. A sample CoA is not the commercial-load ISO 10993-7 sibling; that file is Rec 2-275 until FDA moves it.¹⁶

Which sibling files still sit beside adoption: ISO 11607 commercial pack, ISO 10993-7 residuals, remaining life at a named dock, and why pharma three-batch PPQ is the wrong file?

A successful product adoption rationale under AAMI TIR28:2016/(R)2020 does not authorize commercial release on its own.¹ Ethylene oxide sterilization sits within an interdependent four-pillar compliance structure. When a buyer accepts an inbound commercial lot, three additional sibling files must be audited alongside the TIR28 adoption report.

The Three Mandatory Sibling Files

1. ISO 11607-1 and ISO 11607-2 Sterile Barrier Packaging Validation: A product adoption file evaluates sterilization challenge; it does not replace packaging validation. When introducing a new blister, request the commercial-pack ISO 11607 file. US Rec 14-594 and 14-595 name the 2019 editions including AMD1:2023; Rec 14-530 and 14-531 remain acceptable in premarket declarations of conformity until 20 December 2026. See which ISO 11607 packaging declaration of conformity survives 20 December 2026 and the packaging HOW neighbour on ISO 11607-1 and ISO 11607-2 packaging validation, aging and lot-release tests.
2. ISO 10993-7 Ethylene Oxide Residual Dissipation and Aeration: Ethylene oxide (EO) and its reaction byproduct ethylene chlorohydrin (ECH) are toxic, mutagenic, and irritating compounds. ISO 10993-7 specifies allowable limits based on patient contact duration. A sample CoA is not the commercial-load residual file. US incoming files should still name FDA Rec 2-275 (ISO 10993-7:2008 including Cor 1 and Amd 1), not Rec 2-258 (ISO 10993-1) and not an unrecognised 2026 header.¹⁶ For the edition clock, see which ISO 10993-7 edition still governs an EO residual CoA.
3. Contractual Remaining Shelf Life at the Delivery Dock: While ISO 11607 establishes sterile barrier stability, commercial tenders frequently impose remaining shelf-life clauses (e.g. 75%, 80%, or two-thirds remaining at port of entry). As established in our procurement benchmark on remaining shelf life at a named delivery point versus ISO 11607 and ISO 11135, remaining shelf life is an operational contract SLA—not an engineering statute. It must be explicitly defined in purchase order terms tied to Incoterms 2020 handover points.

Quality auditors must also recognize why borrowing pharmaceutical validation concepts is invalid in medical device ethylene-oxide adoption. Overseas manufacturers frequently present 'three consecutive commercial PPQ batches' as proof of process validation. Three routine full-exposure lots are not a Rec 14-603 adoption rationale and are not a substitute for the Rec 14-529 cycle file. Citing generic ISO 13485 Clause 7.5.6 slogans without a TIR28 overlay for the quoted commercial configuration fails the incoming test. TIR28 is also not an ISO 11137 radiation VDmax file; see ISO 11137 radiation sterilization validation acceptance. For QMSR process-control file review, consult QMSR production and process-control file review before the first commercial lot.

Worked examples: a CE-marked Adult circumcision blister versus a Children size, an NMPA-only stapler, a sterile needle with no public EO cycle, and why laser-fiber, NPWT dressing and NOVACURE are out of this EO family

To demonstrate how AAMI TIR28 product adoption rules apply to physical product lines, consider four worked examples and four strict boundary exclusions drawn directly from the approved VEMERIX surgical and consumable portfolio truth.¹¹¹²

Four Worked Portfolio Examples

Case 1: The CE-Marked Circumcision Device (Adult Ring vs Pediatric Ring Adoption). VEMERIX manufactures a disposable circumcision ring platform registered under NMPA Class II (Lu Mech Reg. 20172020238) with CE certification (CE: Yes).¹¹ It is supplied sterile in individual blister packs across 14 size codes, divided into Adult and Children variants.¹¹ For clinical and commercial SKU selection logic, see our analysis on disposable circumcision device sizing and Adult versus Children portfolio selection.¹¹

Adoption Analysis: If a distributor's initial file validated an Adult 26 mm device as the master product, quoting a Children 12 mm device is an adoption trigger, not a closed cycle certificate.¹ Public product data records EO sterilization, individual blister, and Adult versus Children variants; it does not publish a TIR28 certificate covering every size.¹¹ The engineering file must show whether the smaller geometry and any downsized blister are an equal, lesser or greater challenge than the validated representative. If the Children SKU uses a different blister, the ISO 11607 commercial-pack sibling sits beside that rationale.

Case 2: The Disposable Circumcision Stapler (Invalid Family Collapse). The VEMERIX Disposable Circumcision Stapler is an NMPA Class II device (Lu Mech Reg. 20192020192) specified as Factory EO sterilized.¹² Unlike the circumcision ring, the public product page does not record a CE mark.¹²

Adoption Analysis: An incoming buyer cannot treat the circumcision stapler as adopted into the circumcision ring's EO family from a shared factory label.¹⁰ Public product data records a different design (one-pass cut-and-staple anastomosis versus a self-detaching ring), Factory EO sterilization, and no CE mark.¹² STERIS's public HOW groups families by configuration, materials, density, packaging, components, design and/or challenge; collapsing a stapler into a ring family without that comparison is the failure mode this page is written to catch.¹⁰ The ring's CE mark cannot be transferred to the stapler.¹²

Case 3: The Circumcision Anastomat Kit (Kit-variant trigger). The Circumcision Anastomat Kit (Lu Mech Reg. 20162020372) is an EO-sterilized Adult and Children kit that pairs the anastomat with the consumables required for the procedure.¹³

Adoption Analysis: A kit that adds procedural consumables to the anastomat is a different configuration, materials mix and load than a standalone device.¹⁰ A standalone stapler or ring adoption file does not, by itself, adopt the bundled kit; treat the kit as its own loading challenge under Rec 14-603.¹

Case 4: Disposable Sterile Circumcision Device (Separate Regulatory Registration). Registered under Lu Mech Reg. 20222021157, this factory EO sterilized SKU features an independent design.¹⁴ Even if manufactured in the same cleanroom facility, a separate registration number requires an explicit technical bridge confirming that its internal challenge does not exceed the master PCD.¹⁰

Four Critical Portfolio Exclusions

Quality engineering and procurement teams must maintain strict negative boundaries when auditing manufacturer product matrices:

• Sterile Single-Use Injection Needle: An NMPA Class III sterile device included in the VEMERIX aesthetic injection portfolio.¹⁵ While supplied sterile and single-use, public product records do not specify an ethylene oxide cycle. It must never be assumed into an EO family from marketing text without primary validation records.
• Disposable Medical Laser Fiber: An NMPA Class II device (Lu Mech Reg. 20192010517) supplied sterile and individually packed for 1470 nm vascular workflows. The product catalog specifies no sterilization modality; it must not be claimed as an EO-sterilized device.
• Disposable NPWT Drainage Dressing Kit: An NMPA Class II wound therapy dressing. Public specifications do not specify terminal sterilization; it must not be represented as an EO family member.
• NOVACURE Semiconductor Laser Treatment System: A partner-supplied Class III capital console (Guangdong Yunshang white-label production, Guo Xie Zhu Zhun 20253011190). It is non-sterile capital electronic equipment, not manufactured by Medison, and completely excluded from sterile consumables adoption.

Distributor and OEM RFQ checklist: Rec 14-529 cycle pack, Rec 14-603 adoption rationale for the quoted commercial configuration, Annex E not accepted as adoption, and the documents to request

To prevent border seizures, notified body non-conformances, and hospital receiving quarantine, international distributors and OEM buyers should integrate the following four-stage audit protocol into their commercial Request for Quotation (RFQ) and incoming inspection procedures.¹²

The Four-Stage Document Acceptance Protocol

1. Stage 1: Primary Cycle Validation Dossier (ISO 11135:2014 / FDA Rec 14-529): Request the executive summary of the sterilization validation report. Verify that the cycle was validated under ISO 11135:2014. Confirm the chamber identification, operating cycle parameters, and the exact master product and internal PCD used during performance qualification.²
2. Stage 2: Product Adoption Technical Rationale (AAMI TIR28:2016/(R)2020 / FDA Rec 14-603): If the quoted commercial SKU, size run, or blister packaging differs from the master product, demand a Rec 14-603 adoption rationale or a documented greater-challenge PQ.¹ STERIS's public TechTip assesses design, materials, sterile barrier and load configuration against a worst-case family representative or PCD.¹⁰ Explicitly verify that the supplier has not cited Annex E single-batch release as a substitute for adoption.⁴
3. Stage 3: Sibling File Verification (Packaging & Residuals): Demand the ISO 11607-1/-2 packaging validation report for the specific commercial blister or pouch, including ASTM F88 seal peel strength and ASTM F1929 dye penetration data. Demand the ISO 10993-7 gas chromatography Certificate of Analysis (CoA) demonstrating that ethylene oxide and ethylene chlorohydrin residuals are below allowable limits under the commercial packaging and pallet configuration.
4. Stage 4: Routine Lot Release Dossier (Per-Shipment Inspection): Prior to releasing payment or customs entry, audit the per-lot release documentation: Certificate of Sterilization confirming the validated cycle run number; biological indicator incubation records or parametric physical release logs; and carton labeling confirming sterile lot number, expiration date, and UDI matching the commercial invoice.

Where VEMERIX fits—and where due diligence still begins

VEMERIX—the international brand of Weihai Medison Medical Equipment Co., Ltd.—operates as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery, and perioperative care. Within its surgical urology core, Medison publishes NMPA-registered single-use circumcision devices, including the CE-marked Circumcision Device ring platform.¹¹

When partnering with international distributors and OEM private-label brands, VEMERIX can discuss the current ISO 11135:2014 cycle pack for the quoted EO family and the adoption rationale needed when the commercial size, blister or load was not the sampled configuration.¹¹¹ That discussion is not a claimed TIR28 certificate covering every unquoted size.

However, due diligence still begins with the international buyer. VEMERIX does not issue generic, blanket statements claiming that a single cycle certificate automatically covers unquoted device modifications or third-party accessory kits. We encourage prospective distributors, clinical procurement committees, and OEM partners to review our complete regulatory and quality documentation. Prospective partners can request cycle validation summaries, AAMI TIR28 adoption rationales, ISO 11607 packaging reports, and technical dossiers directly by visiting our VEMERIX Quality & Regulatory portal, exploring our surgical portfolio via Products, or opening an engineering inquiry via Contact Us.

Frequently Asked Questions

Does FDA Rec 14-529 adopt a new circumcision size into an existing EO family?

No. FDA Rec 14-529 recognizes ISO 11135:2014 (Second Edition including Amendment 1:2018) as the standard for cycle development, validation, and routine processing.² It establishes that a validated sterilization cycle exists for a defined master product and internal PCD. Adopting a newly introduced size, modified blister tray, or different polymer resin requires a separate technical evaluation under AAMI TIR28:2016/(R)2020 (FDA Rec 14-603).¹

Is AAMI TIR28:2016/(R)2024 the FDA-recognized designation on 12 September 2026?

No. While AAMI's public catalogue currently lists TIR28:2016/(R)2024, the US FDA Rec 14-603 designation remains AAMI TIR28:2016/(R)2020.¹ US declarations of conformity should match that SIS string until the recognition entry changes. This page does not invent a technical delta between the two reaffirmation years.

Can Annex E single-batch release replace a TIR28 adoption file?

No. ISO 11135:2014/Amd 1:2018 revises Annex E as Single batch release, and FDA Rec 14-529 recognizes that amendment.⁴² Rec 14-603 separately recognizes TIR28 for product adoption and process equivalence.¹ A single-batch-release title is not a standing adoption file for the next commercial lot. This page does not reconstruct paywalled Annex E protocol tables.

Is ISO/FDIS 11135 the in-force cycle standard for a 2026 commercial lot?

No. The draft third edition (ISO/DIS 11135, catalogue 81509) was cancelled at stage 40.98 on 16 May 2024.⁵ The successor project, ISO/FDIS 11135 (catalogue 90088), remains under development at stage 50.00 without formal publication.⁶⁷ ISO 11135:2014 plus Amd 1:2018 remains the published ISO cycle edition and Rec 14-529; FDIS is not that file.³

If the sample was 50 pieces, does that adopt a 2,000-piece commercial pallet?

No. A 50-piece sample is a different load configuration from a 2,000-piece commercial pallet.¹⁰ STERIS's public TechTip treats load configuration as an adoption assessment item and requires full PQ if the candidate is a greater challenge. A sample piece-count is not a validated load, worst-case product or internal PCD.

Does a pharma three-batch PPQ close EO product adoption?

No. Three routine production batches are not Rec 14-603. A pharma-style PPQ slogan does not adopt a new size, blister or load into an EO family, and it is not a substitute for the Rec 14-529 cycle file. See the QMSR production-file neighbour for why 7.5.6 slogans are the wrong overlay.

Does remaining shelf life at the dock prove the commercial configuration was adopted?

No. Remaining shelf life at a named delivery point is a contract overlay, not Rec 14-603. See remaining shelf life at a named delivery point versus ISO 11607 and ISO 11135. It does not prove the commercial configuration was adopted into the EO family.

Does VEMERIX already publish a TIR28 certificate covering every Adult and Children size?

No. VEMERIX does not publish a blanket TIR28 certificate covering every Adult and Children size. The company can discuss the current Rec 14-529 cycle pack and the Rec 14-603 adoption rationale for the quoted commercial configuration; due diligence still begins with matching that configuration to the validated challenge.¹¹